Profile data is unavailable for this security.
About the company
Galera Therapeutics, Inc. is a biopharmaceutical company focused on developing a pipeline of novel, therapeutic candidates that have the potential to transform radiotherapy in cancer. The Company’s lead product candidate, avasopasem manganese (avasopasem), is a highly selective small molecule dismutase mimetic that the Company is developing for the reduction of severe oral mucositis (SOM) in patients with head and neck cancer (HNC), the reduction of esophagitis in patients with lung cancer, and the reduction of cisplatin-induced kidney damage in patients with cancer. The Company’s second product candidate, rucosopasem manganese (rucosopasem), is in development to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. Rucosopasem is an orphan drug designation and orphan medicinal product designation for the treatment of pancreatic cancer.
- Revenue in USD (TTM)0.00
- Net income in USD-45.75m
- Incorporated2012
- Employees7.00
- LocationGalera Therapeutics Inc45 Liberty Blvd., Suite 230MALVERN 19355United StatesUSA
- Phone+1 (610) 725-1500
- Fax+1 (302) 636-5454
- Websitehttps://www.galeratx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Burzynski Research Institute Inc | 0.00 | -1.42m | 5.52m | 2.00 | -- | -- | -- | -- | -0.0108 | -0.0108 | 0.00 | -0.001 | 0.00 | -- | -- | -- | -153,444.30 | -15,304.89 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -45.74 | -- | -- | -- |
| Notable Labs Ltd | 311.00k | -12.39m | 5.59m | 16.00 | -- | 0.4845 | -- | 17.99 | -2.31 | -2.31 | 0.0622 | 1.28 | 0.0142 | -- | -- | 19,437.50 | -56.70 | -52.02 | -74.10 | -62.09 | 37.30 | 60.19 | -3,984.24 | -3,636.93 | -- | -- | 0.0271 | -- | -52.89 | -11.93 | 65.13 | -- | -50.69 | -- |
| Enzolytics Inc | 0.00 | -119.19k | 6.06m | 2.00 | -- | -- | -- | -- | -0.106 | -0.106 | 0.00 | -1.04 | 0.00 | -- | -- | -- | -369.52 | -- | -- | -- | -- | -- | -- | -- | -- | -4.30 | -- | -- | -100.00 | -- | -9.35 | -- | -- | -- |
| Virios Therapeutics Inc | 0.00 | -5.07m | 6.40m | 4.00 | -- | -- | -- | -- | -0.2673 | -0.2673 | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 56.76 | -- | -- | -- |
| Xenetic Biosciences Inc | 2.44m | -4.47m | 6.42m | 4.00 | -- | 0.7405 | -- | 2.63 | -2.92 | -2.92 | 1.59 | 5.63 | 0.2116 | -- | -- | 611,240.00 | -38.71 | -48.91 | -41.54 | -52.82 | -- | -- | -182.95 | -682.42 | -- | -- | 0.00 | -- | 48.80 | -- | 36.90 | -- | -- | -- |
| Alaunos Therapeutics Inc | 6.00k | -26.77m | 6.47m | 1.00 | -- | 1.35 | -- | 1,078.18 | -16.73 | -16.73 | 0.0038 | 3.00 | 0.0002 | -- | 12.00 | 6,000.00 | -97.94 | -74.83 | -147.22 | -89.57 | -- | -- | -446,233.30 | -10,508.06 | -- | -19.25 | 0.00 | -- | -99.83 | -49.08 | 6.86 | -- | -15.56 | -- |
| Marizyme Inc | 549.70k | -69.02m | 6.59m | 11.00 | -- | -- | -- | 11.99 | -1.42 | -1.42 | 0.0081 | -0.0822 | 0.0184 | 1.65 | 14.06 | 49,972.73 | -230.68 | -59.02 | -531.63 | -64.47 | 71.17 | 70.38 | -12,555.69 | -9,435.92 | 0.0279 | -0.5837 | 1.92 | -- | 176.59 | 99.98 | -71.22 | -- | -- | -- |
| Galera Therapeutics Inc | 0.00 | -45.75m | 6.63m | 7.00 | -- | -- | -- | -- | -0.9971 | -0.9971 | 0.00 | -2.48 | 0.00 | -- | -- | 0.00 | -115.30 | -83.69 | -142.79 | -97.54 | -- | -- | -- | -- | -- | -6.49 | 9.23 | -- | -- | -- | 5.05 | -- | -29.84 | -- |
| Tenax Therapeutics Inc | 0.00 | -10.10m | 6.75m | 5.00 | -- | 0.5428 | -- | -- | -24.52 | -24.52 | 0.00 | 6.35 | 0.00 | -- | -- | 0.00 | -67.96 | -199.16 | -75.66 | -285.64 | -- | -- | -- | -- | -- | -105.12 | 0.0322 | -- | -- | -- | 30.21 | -- | -- | -- |
| Chromocell Therapeutics Corp | 0.00 | -8.98m | 6.75m | 4.00 | -- | 5.97 | -- | -- | -1.66 | -1.66 | 0.00 | 0.196 | 0.00 | -- | -- | 0.00 | -440.01 | -- | -- | -- | -- | -- | -- | -- | -- | -7.20 | 0.00 | -- | -- | -- | -200.20 | -- | -- | -- |
| NuCana PLC (ADR) | 0.00 | -34.33m | 7.42m | 25.00 | -- | 0.6107 | -- | -- | -306.86 | -306.86 | 0.00 | 5.75 | 0.00 | -- | -- | 0.00 | -72.34 | -41.01 | -125.17 | -48.07 | -- | -- | -- | -- | -- | -- | 0.0324 | -- | -- | -- | 13.71 | -- | -21.70 | -- |
| Pulmatrix Inc | 11.68m | -8.85m | 7.67m | 22.00 | -- | 0.4033 | -- | 0.6564 | -2.42 | -2.42 | 3.20 | 5.21 | 0.3517 | -- | 17.84 | 531,090.90 | -26.63 | -46.91 | -30.21 | -58.12 | -- | -- | -75.73 | -238.04 | -- | -- | 0.00 | -- | 20.21 | 116.62 | 25.03 | -- | 104.29 | -- |
| GlucoTrack Inc | 0.00 | -8.74m | 7.72m | 6.00 | -- | 20.07 | -- | -- | -1.87 | -1.87 | 0.00 | 0.0703 | 0.00 | -- | -- | 0.00 | -520.58 | -94.01 | -2,110.63 | -142.35 | -- | -- | -- | -10,447.96 | -- | -- | 0.3415 | -- | -- | -- | -60.02 | -- | -- | -- |
Data as of Jul 24 2024. Currency figures normalised to Galera Therapeutics Inc's reporting currency: US Dollar USD
5.54%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| abrdn, Inc.as of 31 Mar 2024 | 898.37k | 1.65% |
| Deerfield Management Co. LPas of 17 Feb 2023 | 530.40k | 0.98% |
| Geode Capital Management LLCas of 31 May 2024 | 402.75k | 0.74% |
| Atom Investors LPas of 31 Mar 2024 | 356.20k | 0.66% |
| UBS Securities LLCas of 31 Mar 2024 | 293.50k | 0.54% |
| G1 Execution Services LLCas of 31 Mar 2024 | 286.18k | 0.53% |
| Summit Trail Advisors LLCas of 31 Mar 2024 | 147.66k | 0.27% |
| RBC Dominion Securities, Inc. (Investment Management)as of 31 Mar 2024 | 35.00k | 0.06% |
| Group One Trading LPas of 31 Mar 2024 | 32.72k | 0.06% |
| Kestra Advisory Services LLCas of 31 Mar 2024 | 32.25k | 0.06% |
More ▼
Data from 31 Mar 2024 - 15 May 2024Source: FactSet Research Systems Inc.
